We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.60 | 9.40 | 9.80 | 9.60 | 9.60 | 9.60 | 114,837 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.44 | 89.07M |
Date | Subject | Author | Discuss |
---|---|---|---|
15/3/2023 09:50 | I said "can" - i.e. got quoted at 16.43 - I already more than enough! | nigelpm | |
15/3/2023 09:46 | We need to remember what type of cancers and end stage patients that Moditope is actually working on, e.g. HGSOC (high-grade serous ovarian cancer) is a very aggressive ovarian cancer. The cancer grows slowly in your fallopian tubes at first. But it then spreads rapidly once it reaches your ovaries. Unfortunately, most people with HGSOC have advanced (metastatic) ovarian cancer by the time they get a diagnosis. 5 year survival rates are 15 per cent. | marcusl2 | |
15/3/2023 09:40 | anyway .. have you bought your "plenty" ... Nigel | inanaco | |
15/3/2023 09:39 | it's quite a bit when you hold 1.3m | inanaco | |
15/3/2023 09:38 | Why quibble over 0.5p! Crazy. | nigelpm | |
15/3/2023 09:38 | yes now you can, but not at 16p ... and 16.33 so how many have you just bought ? | inanaco | |
15/3/2023 09:32 | I can buy plenty - change your broker Inanaco. | nigelpm | |
15/3/2023 09:24 | "£700 at 16.33" - Place your bets | the real lozan | |
15/3/2023 09:17 | This could well be the event where Modi/Scancell hits the main news channels. | chillpill | |
15/3/2023 09:02 | Lindy will have more data by April 18, 2023, 1:30 PM - 5:00 PM in Florida so that is 5.30 - 9pm BST UK. Hopefully she can boast about additional partial responses by then. I am eager to see how Modi-1 plus CPI is doing. When the data is good and they prove the method of operation then I would expect numerous offers for Moditope or the company. April 14, 2023: Late-Breaking and Clinical Trials Abstract Texts Posted to Online Itinerary Planner and Meeting App (12 noon ET) | marcusl2 | |
15/3/2023 08:45 | Looks like the great reveal to the World is approaching. Good news! | chillpill | |
15/3/2023 08:31 | For those that have sold down ...... good luck buying back .... 27 mins to buy £1200 worth Scancell presenting ... Modi1 is amazing | inanaco | |
15/3/2023 08:29 | £700 at 16.33 | inanaco | |
15/3/2023 08:18 | got £500 at 16p .... but nothing else | inanaco | |
15/3/2023 08:16 | trying to get a £1200 top up ......... unavailable | inanaco | |
15/3/2023 08:08 | can't get a price | inanaco | |
15/3/2023 05:09 | Yes great find by Bermuda ....... this is gold dust !! and the great news .... its Next years, tax year .... ISA April 5th | inanaco | |
14/3/2023 22:22 | Share price action here has been very frustrating (Notwithstanding the recent fall across markets generally). I do wonder if there's a concern over funding that'll be needed down the line. | nigelpm | |
14/3/2023 22:20 | Burble RE: AACR 2023Today 22:03 The full text of the Clinical Trial and Late-Breaking Abstracts will be posted to the AACR Online Itinerary Planner and the Meeting App no earlier than 12:00 p.m. U.S. ET on Friday, April 14, 2023, except those abstracts that are selected for inclusion in the official AACR press program. Abstracts that are featured in the official AACR press program will be made publicly available at the date and time of presentation, either at the meeting or an official AACR press conference. In previous years, abstracts accepted for presentation at the AACR Annual Meeting were published in an online-only Proceedings supplement to the AACR journal Cancer Research after the conclusion of the meeting. Beginning in 2023, the Proceedings supplement will be published prior to the meeting in two parts. Part 1 of the online Proceedings (regular abstracts) will be published on Friday, March 31, and Part 2 (clinical trials and late-breaking abstracts) will be published on Friday, April 14. Revised Proceedings supplements containing the full text of embargoed abstracts as well as any late change will be published in Cancer Research approximately one month after the meeting. | marcusl2 | |
14/3/2023 22:16 | Bermudashorts AACR 2023Today 21:38 Am delighted to see that Scancell have had an abstract accepted for presentation at the AACR Annual Meeting. This is one of the, if not the biggest scientific conferences in the world. The title of the abstract is:- 'Modi-1, anti-citrullinated neoepitope vaccine alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal and ovarian carcinoma: protocol for the ModiFY phase I/II basket clinical Trial' It will be presented by Lindy Durrant on April 18, 2023, 1:30 PM - 5:00 PM Good stuff - have been waiting since 2015 to see Scancell present at AACR/ASCO! | marcusl2 | |
14/3/2023 21:38 | So Pfizer have spent 43bn on a Company with treatments for Cancer after getting billions of needles in arms over the last couple of years. I am sure it is just a coincidence. Why aren't they interested in Scancell, have you ever thought that maybe Scancell's vaccines are too safe, not enough ADR's, no money in safe, effective cures. Scancell always the Bridesmaid never the Bride. I have been telling you for the last 18 months about the proliferation of Cancer and Doctors around the world reporting the aggressiveness and Patients going to straight to stage 4 and skipping stages 1,2 and 3. | panama7 | |
14/3/2023 15:46 | Synaffix and MacroGenics unveiled their antibody drug-conjugate (ADC) collaboration of four additional ADC programs, increasing the potential deal value by $2.2 billion Pfizer's announcement Monday that it had bought cancer behemoth Seagen for $43 billion, in large part to capitalize on the company’s ADC prowess, served as another reminder of the attention the modality is getting. Centered entirely around the antibody glycan, Synaffix has established a simple, rapidly deployable technology platform, enabling any company with an antibody to develop a proprietary, best-in-class ADC or bispecifics. | marcusl2 | |
14/3/2023 10:01 | " Beautiful to watch." - Tarquin, No,I was talking about the European Red Kite Unclear on the location (Thailand or Devon) to which you refer The reason I refer to the wildlife is to highlight the benefits of a 'stressfree' lifestyle,,,as opposed to the obvious STRESSFUL drive which is present in most of the landan based thinking on these forums. | the real lozan | |
14/3/2023 08:25 | Interesting that some of you are supporting the saving of SVB, a Bank where the Board awarded themselves 5m in bonuses last week and were busy selling shares to the tune of millions of dollars. Not surprised that some of you support this type of criminality after all some of you believe it is a positive to link Scancell to Pfizer the biggest criminal drug dealer on the planet, the Mexican cartels don't come close. | panama7 | |
13/3/2023 23:56 | Is that the large Brahminy kite with the white head ? In this area with many estuaries, some waterside restaurants feed them and then we see probably hundreds, circling and feeding off the river. Beautiful to watch. | torquayfan |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions